Phlorizin is a non-selectiveSGLTinhibitor withK_is of 300 and 39 nM forhSGLT1andhSGLT2, respectively. Phlorizin is also aNa⁺/K⁺-ATPaseinhibitor.

Phlorizin is a non-selective SGLT inhibitor with K_is of 300 and 39 nM for hSGLT1 and hSGLT2, respectively^[1]. Phlorizin is also a Na⁺/K⁺-ATPase inhibitor^[2]. Phlorizin at 2×10^-4M inhibits Na⁺and Rb⁺-activated ATPase activities in human red cell membranes by 43 %. At 1 mM and 7 mM RbCl, rubidium uptake is not changed or is slightly inhibited (less than 15 %) by 2×10^-4M Phlorizin^[2]. Cell viability is not significantly altered by doses of Phlorizin<100 μm. pretreating cells with phlorizin does not significantly reduce nitrite or pge₂levels. Phlorizin does not suppress IL-6 or TNF-α production, although 100 μM Phlorizin can significantly inhibit TNF-α expression^[3].

Prior to Phlorizin treatment, the blood glucose level in SDT fatty rats is 370±49 mg/dL. Six hours after dosing, the blood glucose level in the Phlorizin treated group decreases to an almost normal level (139±32 mg/dL). Phlorizin-treated SDT fatty rats are heavier than vehicle-treated SDT fatty rats after 12 weeks. Phlorizin treatment significantly decreases glucose excretion and delays insulin decreases. Creatinine clearance decreases significantly with Phlorizin treatment. 23 weeks of Phlorizin treatment prevents the decrease of nerve fibers (23.6±3.2 fibers/mm). Retinal abnormalities are completely prevented with Phlorizin^[4].

436.41

Solid

C₂₁H₂₄O₁₀

60-81-1

根皮苷；根皮甙

• Flavonoids
• Dihydrochalcones

• Phenols
• Polyphenols

• Plants
• Rosaceae
• Malus pumilaMill.

Room temperature in continental US; may vary elsewhere.

DMSO : ≥ 50 mg/mL(114.57 mM)

H₂O : 1 mg/mL(2.29 mM;Need ultrasonic)

*"≥" means soluble, but saturation unknown.

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 20%HP-β-CDin saline

  Solubility: 15.15 mg/mL (34.72 mM); Clear solution; Need ultrasonic
• 2.

  请依序添加每种溶剂： 10% DMSO    40%PEG300   5%Tween-80   45% saline

  Solubility: ≥ 2.5 mg/mL (5.73 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (5.73 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

  将 0.9 g 氯化钠，完全溶解于 100 mL ddH2O 中，得到澄清透明的生理盐水溶液
• 3.

  请依序添加每种溶剂： 10% DMSO    90% (20%SBE-β-CDin saline)

  Solubility: ≥ 2.5 mg/mL (5.73 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (5.73 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

  将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
• 4.

  请依序添加每种溶剂： 10% DMSO    90%corn oil

  Solubility: ≥ 2.5 mg/mL (5.73 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (5.73 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

• 5.

  请依序添加每种溶剂： PBS

  Solubility: 1.75 mg/mL (4.01 mM); Clear solution; Need ultrasonic and warming and heat to 60℃